PD-1 Progress May Shorten The Life Of Other Drugs
Executive Summary
With PD-1 immunotherapy continuing to make gains in melanoma, will Yervoy and targeted BRAF/MEK combos from Novartis, Roche and Array BioPharma get relegated to second-class status?
You may also be interested in...
Heat Biologics Tightens Belt To Reach Late-2016 Inflection Points
Biotech striving to hold on financially until it can deliver top-line data for bladder and lung cancer immunotherapy candidates, but then it will have to content with Roche entering the bladder cancer market with its PD-L1 inhibitor.
Genentech Catching Up In Melanoma With Cotellic Approval
FDA clears Cotellic/Zelboraf combination, but the company already is testing the addition of a PD-L1 inhibitor.
Bristol’s Opdivo Delay May Help It Beat Out BRAF Inhibitors
Firm announces three-month user fee extension for first-line melanoma claim for Opdivo, but the firm’s statement suggests a silver lining.